These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32486990)

  • 1. [Opioid Agonist Therapy (OAT) for opioid dependency].
    Köck P; Strasser J
    Ther Umsch; 2020; 77(1):29-36. PubMed ID: 32486990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years.
    Nordt C; Vogel M; Dey M; Moldovanyi A; Beck T; Berthel T; Walter M; Seifritz E; Dürsteler KM; Herdener M
    Addiction; 2019 Jan; 114(1):103-111. PubMed ID: 30209840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global opioid agonist treatment: a review of clinical practices by country.
    Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
    Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
    Brothers TD; Fraser J; MacAdam E; Morgan B; Webster D
    Drug Alcohol Rev; 2022 Feb; 41(2):430-434. PubMed ID: 34347327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.
    Dematteis M; Auriacombe M; D'Agnone O; Somaini L; Szerman N; Littlewood R; Alam F; Alho H; Benyamina A; Bobes J; Daulouede JP; Leonardi C; Maremmani I; Torrens M; Walcher S; Soyka M
    Expert Opin Pharmacother; 2017 Dec; 18(18):1987-1999. PubMed ID: 29183228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant Heroin and Cocaine Use among Opioid-Dependent Patients during Methadone, Buprenorphine or Morphine Opioid Agonist Therapy.
    Gastberger S; Baumgartner MR; Soyka M; Quednow BB; Hulka LM; Herdener M; Seifritz E; Mutschler J
    Eur Addict Res; 2019; 25(4):207-212. PubMed ID: 31067528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study.
    Bech AB; Clausen T; Waal H; Šaltytė Benth J; Skeie I
    BMC Health Serv Res; 2019 Jul; 19(1):440. PubMed ID: 31266495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
    Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
    Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: A systematic review of the neurocognitive effects of buprenorphine and methadone treatment.
    Mindt MR; Coulehan K; Aghvinian M; Scott TM; Olsen JP; Cunningham CO; Arias F; Arnsten JH
    J Subst Abuse Treat; 2022 Apr; 135():108644. PubMed ID: 34857427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022.
    Bharat C; Chidwick K; Gisev N; Farrell M; Ali R; Degenhardt L
    Int J Drug Policy; 2024 Jan; 123():104255. PubMed ID: 38029481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study.
    Paul LA; Bayoumi AM; Chen C; Kocovska E; Smith BT; Raboud JM; Gomes T; Kendall C; Rosella LC; Bitonti-Bengert L; Rush B; Yu M; Spithoff S; Crichlow F; Wright A; Watford J; Besharah J; Munro C; Taha S; Nosyk B; Strike C; Manson H; Kahan M; Leece P
    Addiction; 2023 Apr; 118(4):686-697. PubMed ID: 36401610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
    Wei LC; Chan HY
    Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accessing opioid agonist treatment in prison in England and Scotland remains problematic - the views of people with lived experience.
    Webster R; Fearns C; Harriott P; Millar L; Simpson J; Wallace J; Wheatley M
    Int J Prison Health (2024); 2024 May; 20(2):143-155. PubMed ID: 38984599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
    Farrell MacDonald S; Russell C; Beauchamp T; Derkzen D; Fischer B
    Int J Drug Policy; 2022 Feb; 100():103480. PubMed ID: 34656817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.
    Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
    Addiction; 2021 Dec; 116(12):3473-3481. PubMed ID: 33999458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.